Theravance Biopharma, Inc.

Theravance Biopharma, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • TBPH (NGM)

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving Average - What's Next? - MarketBeat
MarketBeat • Jan 3
Here's Why Shares in Theravance Biopharma Exploded Today - The Motley Fool
The Motley Fool • Nov 11
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
PR Newswire • Nov 10
mF International, Theravance Biopharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Benzinga • Jan 5
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review - Yahoo Finance
Yahoo Finance • Dec 12

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Theravance Biopharma, Inc. had layoffs?
No layoff events have been recorded for Theravance Biopharma, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Theravance Biopharma, Inc. have?
Theravance Biopharma, Inc. has approximately 97 employees.
What industry is Theravance Biopharma, Inc. in?
Theravance Biopharma, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Theravance Biopharma, Inc. a publicly traded company?
Yes, Theravance Biopharma, Inc. is publicly traded under the ticker symbol TBPH on the NGM. The company has a market capitalization of approximately $0.95 billion.
Where is Theravance Biopharma, Inc. headquartered?
Theravance Biopharma, Inc. is headquartered in South San Francisco, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.